{"id":4859,"date":"2024-04-19T08:16:02","date_gmt":"2024-04-19T08:16:02","guid":{"rendered":"https:\/\/regensight.com\/ritsight-is-the-riboflavin-ophthalmic-solution-with-highest-performance-for-corneal-cross-linking\/"},"modified":"2024-04-19T08:16:02","modified_gmt":"2024-04-19T08:16:02","slug":"ritsight-is-the-riboflavin-ophthalmic-solution-with-highest-performance-for-corneal-cross-linking","status":"publish","type":"post","link":"https:\/\/regensight.com\/en\/ritsight-is-the-riboflavin-ophthalmic-solution-with-highest-performance-for-corneal-cross-linking\/","title":{"rendered":"RitSight is the riboflavin ophthalmic solution with highest performance for corneal cross-linking"},"content":{"rendered":"<p>Glad to share the outcomes of a recent manuscript, published on Graefe\u2019s Archive for Clinical &amp; Experimental Ophthalmology, assessing the performance of several clinically available riboflavin ophthalmic formulations for corneal cross-linking.<\/p>\n<p>The C4V CHROMO4VIS theranostics device allowed the quantity of riboflavin permeating the human cornea to be precisely and non-invasively measured with epi-off and epi-on application protocols using the various ophthalmic solutions available in Europe and the United States.<\/p>\n<p>The study demonstrated that RitSight significantly outperforms all available products for the treatment of pathological corneal conditions with corneal cross-linking procedures, with an average of four times the effectiveness of epi-on protocols.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glad to share the outcomes of a recent manuscript, published on Graefe\u2019s Archive for Clinical &amp; Experimental Ophthalmology, assessing the performance of several clinically available riboflavin ophthalmic formulations for corneal cross-linking. The C4V CHROMO4VIS theranostics device allowed the quantity of riboflavin permeating the human cornea to be precisely and non-invasively measured with epi-off and epi-on [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":4856,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":""},"categories":[35],"tags":[],"_links":{"self":[{"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/posts\/4859"}],"collection":[{"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/comments?post=4859"}],"version-history":[{"count":0,"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/posts\/4859\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/media\/4856"}],"wp:attachment":[{"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/media?parent=4859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/categories?post=4859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/tags?post=4859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}